We have seen prolonged tumour growth delay in several PDX tumour models with this treatment regimen, including those with either low or high baseline CXCR4 expression,4 suggesting that it may be broadly applicable in patients with cervical cancer. Here, CXCR4 is linked to cervical carcinoma.